6 Meridian’s Enanta Pharmaceuticals ENTA Stock Holding History

6 Meridian’s Portfolio ENTA Stock Details ENTA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q3	–	Sell	-7,390	Closed	-$325K	–	428
2021 Q2	$325K	Sell	7,390 -88	-1%	-$4.31K	0.03%	222
2021 Q1	$369K	Buy	+7,478	New	+$373K	0.03%	207
2018 Q3	–	Sell	-8,091	Closed	-$938K	–	450
2018 Q2	$938K	Sell	8,091 -89	-1%	-$8.88K	0.1%	118
2018 Q1	$662K	Buy	+8,180	New	+$630K	0.07%	141

Other funds holding ENTA

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return

Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

First Manhattan New York $39.2B AUM 21.04% 1-Year Est. Return

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

KAM

Krensavage Asset Management New York $263M AUM 66.99% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

6 Meridian's ENTA Position: Q3 2021 in Review

6 Meridian sold out of Enanta Pharmaceuticals (ENTA) in Q3 2021, closing a stake of 7,390 shares — an estimated $325K sold.

6 Meridian first reported a position in ENTA in Q1 2018 and held it in 4 quarters. The position peaked at $938K in Q2 2018. 148 funds tracked by Wall St. Rank hold ENTA as of Q3 2021.

6 Meridian reported no remaining Enanta Pharmaceuticals position as of Q3 2021 after selling out during the quarter.
6 Meridian sold 7,390 Enanta Pharmaceuticals shares in Q3 2021, an estimated $325K.
6 Meridian first reported a position in Enanta Pharmaceuticals in Q1 2018 and held it in 4 quarters.
6 Meridian's Enanta Pharmaceuticals position peaked at $938K in Q2 2018.
148 funds tracked by Wall St. Rank held Enanta Pharmaceuticals as of Q3 2021.

Based on 6 Meridian's 13F filing for Q3 2021, filed 3 Nov 2021.